Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family

The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the combination of low plasma anti-HIV-1 Env IgA antibodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with infec...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mattia Bonsignori, Justin Pollara, Anthony A. Moody, Xi Chen, Kwan Ki Hwang, Thaddeus C. Gurley, Daniel M. Kozink, Dawn J. Marshall, John F. Whitesides, Chun Yen Tsao, Georgia D. Tomaras, David C. Montefiori, Guido Ferrari, Hua Xin Liao, Barton F. Haynes, Michael D. Alpert, David T. Evans, Peter B. Gilbert, Ying Huang, Jaranit Kaewkungwal, Sorachai Nitayaphan, Punnee Pitisuttithum, Supachai Rerks-Ngarm, Jerome H. Kim, Nelson L. Michael, George K. Lewis, Anthony DeVico
Other Authors:	Duke University School of Medicine
Format:	Article
Published:	2018
Subjects:	Immunology and Microbiology
Online Access:	https://repository.li.mahidol.ac.th/handle/123456789/14248
Tags:	Add Tag No Tags, Be the first to tag this record!
Institution:	Mahidol University

Similar Items

HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities
by: Justin Pollara, et al.
Published: (2018)

HIV-1- specific IgA monoclonal antibodies from an HIV-1 vaccinee mediate galactosylceramide blocking and phagocytosis
by: Saintedym Wills, et al.
Published: (2019)

Monoclonal antibodies, derived from humans vaccinated with the RV144 HIV vaccine containing the HVEM binding domain of herpes simplex virus (HSV) glycoprotein D, neutralize HSV infection, mediate antibody-dependent cellular cytotoxicity, and protect mice from ocular challenge with HSV-1
by: Kening Wang, et al.
Published: (2018)

Humanized-Single Domain Antibodies (VH/VHH) that Bound Specifically to Naja kaouthia Phospholipase A2 and Neutralized the Enzymatic Activity
by: Charnwit Chavanayarn, et al.
Published: (2018)

Boosting with AIDSvax B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity breadth and potency
by: David Easterhoff, et al.
Published: (2020)

HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions
by: David Easterhoff, et al.
Published: (2020)

Antibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved
by: Kevin Wiehe, et al.
Published: (2018)

Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2
by: Hua Xin Liao, et al.
Published: (2018)

Vaccine-induced HIV-1 envelope gp120 constant region 1-specific antibodies expose a CD4-inducible epitope and block the interaction of HIV-1 gp140 with galactosylceramide
by: S. Moses Dennison, et al.
Published: (2018)

Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial
by: David Easterhoff, et al.
Published: (2018)

Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG
by: Georgia D. Tomaras, et al.
Published: (2018)

Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials
by: David C. Montefiori, et al.
Published: (2018)

HIV-1 envelope glycoproteins from diverse clades differentiate antibody responses and durability among vaccinees
by: Nicole L. Yates, et al.
Published: (2019)

Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection
by: Rena D. Astronomo, et al.
Published: (2018)

Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women
by: Peter B. Gilbert, et al.
Published: (2018)

HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition
by: Heather A. Prentice, et al.
Published: (2018)

Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
by: Pinghuang Liu, et al.
Published: (2018)

Humanized-VH/VHH that inhibit HCV replication by interfering with the virus helicase activity
by: Aninthita Phalaphol, et al.
Published: (2018)

Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques
by: Sampa Santra, et al.
Published: (2018)

Engineering an autonomous VH domain to modulate intracellular pathways and to interrogate the eIF4F complex
by: Frosi, Yuri, et al.
Published: (2023)

Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
by: Nathan I. Nicely, et al.
Published: (2018)

HIV-specific antibody-dependent phagocytosis matures during HIV infection
by: Fernanda Ana-Sosa-Batiz, et al.
Published: (2018)

Antiangiogenic effects of VH02, a novel urea derivative: In vitro and in vivo studies
by: Suwadee Phowichit, et al.
Published: (2018)

CHARACTERIZATION OF DENGUE NEUTRALIZING ANTIBODIES USING RECOMBINANT ANTIBODIES TECHNOLOGY
by: XU MEIHUI
Published: (2015)

USE OF ANTIBODY ENGINEERING TO IMPROVE THE PROPERTIES OF ANTIBODIES AS A REAGENTS
by: ENG HUIYAN
Published: (2015)

Therapeutic Antibodies
by: Chernajovsky, Yuti
Published: (2017)

Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans
by: Lue Ping Zhao, et al.
Published: (2020)

Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against hiv-1
by: Shida Shangguan, et al.
Published: (2022)

Ebola virus antibodies in fruit bats, bangladesh
by: Olival, K.J, et al.
Published: (2020)

Application of Recombinant Antibody Technology for the Development of Anti-Lipid antibodies for Tuberculosis Diagnosis
by: CONRAD CHAN EN ZUO
Published: (2014)

Dengue antibody in thai children from maternally transferred antibody to acquired infection
by: Krisana Pengsaa, et al.
Published: (2018)

Construction of Antibody Library and Production of Polyclonal Antibodies Specific to Human Protein C
by: Prachasuphap A.
Published: (2023)

Vaccine-induced IgG antibodies to V1V2 regions of multiple HIV- 1 subtypes correlate with decreased risk of HIV-1 infection.
by: Zolla-Pazner, Susan, et al.
Published: (2015)

Monoclonal antibodies to quinine
by: Anong Kitjaroentham, et al.
Published: (2018)

Therapeutic Antibodies in Stroke
by: Yu, C.Y, et al.
Published: (2020)

The thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120
by: Nicos Karasavvas, et al.
Published: (2018)

Significance of Acetylcholine Receptor Antibody Titers in Acetylcholine Receptor Antibody-Positive Ocular Myasthenia Gravis: Generalization and Presence of Thyroid Autoimmune Antibodies and Thymoma
by: Supawongwattana M.
Published: (2023)

Antibody-conjugated paramagnetic nanobeads: Kinetics of bead-cell binding
by: Shahid Waseem, et al.
Published: (2018)

Enhancement of labeled alpha-fetoprotein antibodies and antigen-antibody complexes fluorescence with silver nanocolloids
by: Vaschenko, Svetlana, et al.
Published: (2018)

Pemantauan penyakit tungro dengan antibodi monoklonal=Tungro disease monitoring with monoclonal antibody
by: Perpustakaan UGM, i-lib
Published: (1999)